Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1981
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1985 1
1986 2
1989 3
1992 1
1993 2
1994 1
1996 3
1997 1
1998 3
2000 2
2001 1
2002 2
2003 3
2004 4
2005 4
2006 1
2007 1
2008 2
2009 1
2010 3
2011 7
2012 7
2013 6
2014 9
2015 8
2016 8
2017 7
2018 4
2019 4
2020 3
2021 5
2022 1
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Hungry bone syndrome.
Jain N, Reilly RF. Jain N, et al. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):250-255. doi: 10.1097/MNH.0000000000000327. Curr Opin Nephrol Hypertens. 2017. PMID: 28375869 Review.
A severe drop in serum total calcium concentration less than 2.1 mmol/L and/or prolonged hypocalcemia for more than 4 days postparathyroidectomy is called hungry bone syndrome (HBS). Concomitant hypophosphatemia, hypomagnesemia, and hyperkalemia can be seen. Hypocalcemia a …
A severe drop in serum total calcium concentration less than 2.1 mmol/L and/or prolonged hypocalcemia for more than 4 days postparathyroidec …
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.
Thurber KM, Otto AO, Stricker SL. Thurber KM, et al. Am J Health Syst Pharm. 2023 Apr 8;80(8):487-494. doi: 10.1093/ajhp/zxad009. Am J Health Syst Pharm. 2023. PMID: 36629265 Review.
For inclusion in this review, studies must have evaluated potential adverse events associated with PPIs as a primary or secondary objective. Increased risks of bone fracture, acute and chronic kidney disease, gastrointestinal infections, and magnesium deficiency were consi …
For inclusion in this review, studies must have evaluated potential adverse events associated with PPIs as a primary or secondary obj …
European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.
Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Pascual E. Zhang W, et al. Ann Rheum Dis. 2011 Apr;70(4):563-70. doi: 10.1136/ard.2010.139105. Epub 2011 Jan 7. Ann Rheum Dis. 2011. PMID: 21216817
Recognised risk factors for CPPD include ageing, OA and metabolic conditions such as primary hyperparathyroidism, haemochromatosis and hypomagnesaemia; familial forms are rare. ...
Recognised risk factors for CPPD include ageing, OA and metabolic conditions such as primary hyperparathyroidism, haemochromatosis an …
Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature.
Witteveen JE, van Thiel S, Romijn JA, Hamdy NA. Witteveen JE, et al. Eur J Endocrinol. 2013 Feb 20;168(3):R45-53. doi: 10.1530/EJE-12-0528. Print 2013 Mar. Eur J Endocrinol. 2013. PMID: 23152439 Review.
Hungry bone syndrome (HBS) refers to the rapid, profound, and prolonged hypocalcaemia associated with hypophosphataemia and hypomagnesaemia, and is exacerbated by suppressed parathyroid hormone (PTH) levels, which follows parathyroidectomy in patients with severe primar
Hungry bone syndrome (HBS) refers to the rapid, profound, and prolonged hypocalcaemia associated with hypophosphataemia and hypomagnesaem
Magnesium and Vascular Calcification in Chronic Kidney Disease: Current Insights.
Zaslow SJ, Oliveira-Paula GH, Chen W. Zaslow SJ, et al. Int J Mol Sci. 2024 Jan 18;25(2):1155. doi: 10.3390/ijms25021155. Int J Mol Sci. 2024. PMID: 38256228 Free PMC article. Review.
While both hyper- and hypomagnesemia may lead to adverse effects, the consequences associated with hypomagnesemia are often more severe and lasting. Importantly, observational studies have shown that CKD patients with hypomagnesemia have greater vascular calc …
While both hyper- and hypomagnesemia may lead to adverse effects, the consequences associated with hypomagnesemia are often mo …
Cisplatin nephrotoxicity.
Fillastre JP, Raguenez-Viotte G. Fillastre JP, et al. Toxicol Lett. 1989 Mar;46(1-3):163-75. doi: 10.1016/0378-4274(89)90125-2. Toxicol Lett. 1989. PMID: 2650023 Review.
A decrease in renal plasma flow was observed very early on in patients receiving cisplatin at a dose of 20 mg/m2 over a period of 4 h, and an increase in urinary enzymes occurred rapidly. Hypomagnesaemia, hypocalcaemia and hypokalaemia were frequent. The mechanism of cispl …
A decrease in renal plasma flow was observed very early on in patients receiving cisplatin at a dose of 20 mg/m2 over a period of 4 h, and a …
Mechanisms and causes of hypomagnesemia.
Agus ZS. Agus ZS. Curr Opin Nephrol Hypertens. 2016 Jul;25(4):301-7. doi: 10.1097/MNH.0000000000000238. Curr Opin Nephrol Hypertens. 2016. PMID: 27219040 Review.
PURPOSE OF REVIEW: Identification of the mechanisms of magnesium absorption and reabsorption has markedly enhanced our understanding of the causes of hypomagnesemia. RECENT FINDINGS: New gastrointestinal and renal causes of hypomagnesemia have been recently document …
PURPOSE OF REVIEW: Identification of the mechanisms of magnesium absorption and reabsorption has markedly enhanced our understanding of the …
Hypomagnesemia and proton-pump inhibitors.
Famularo G, Gasbarrone L, Minisola G. Famularo G, et al. Expert Opin Drug Saf. 2013 Sep;12(5):709-16. doi: 10.1517/14740338.2013.809062. Epub 2013 Jun 29. Expert Opin Drug Saf. 2013. PMID: 23808631 Review.
Hypomagnesemia may recur after re-challenge with the same or a different PPI and is not clearly dose-related. ...EXPERT OPINION: Although mechanism and incidence rate remain unclear, there seems little doubt that PPIs may cause hypomagnesemia. We should obtain blood
Hypomagnesemia may recur after re-challenge with the same or a different PPI and is not clearly dose-related. ...EXPERT OPINION: Alth
[Pharmacovigilance].
Livio F, Renard D, Buclin T. Livio F, et al. Rev Med Suisse. 2012 Jan 18;8(324):116-9. Rev Med Suisse. 2012. PMID: 23185821 Review. French.
Long-term proton pump inhibitors: A cause of hypomagnesemia. Bisphosphonates: A risk of atypical femoral fractures. Dasatinib: Cases of pulmonary arterial hypertension reported. Lenalidomide: A risk of second primary malignancies. Daptomycine: Cases of eosinophilic …
Long-term proton pump inhibitors: A cause of hypomagnesemia. Bisphosphonates: A risk of atypical femoral fractures. Dasatinib: Cases …
106 results